Agenus

Agenus Announces Appointment of Tom Harrison to Board of Directors

Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline LEXINGTON, Mass. – Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. “Tom’s extensive … Continue reading Agenus Announces Appointment of Tom Harrison to Board of Directors

Parse Biosciences

Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia

Partnership extends access in Asia to Parse’s growing single cell portfolio SEATTLE – Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Taipei-based Prisma Biotech to broaden Parse’s reach in Taiwan and across Asia-Pacific. “We’re excited to empower them to easily take advantage of Parse’s single cell sequencing technology through our partnership with Prisma.” Post this “Biotech, pharma, … Continue reading Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia

Bifrost Biosystems

Bifrost Biosystems Appoints Industry Veteran Jonas Jarvius, PhD as CEO

CAMBRIDGE, Mass – Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS) technologies, today announced the appointment of experienced life sciences industry executive, Jonas Jarvius, PhD, as Chief Executive Officer, President and Director. He brings to Bifrost over 15 years of C-level executive experience from both private and public companies translating innovative technologies into commercial products that impact human health outcomes. “In my career, I … Continue reading Bifrost Biosystems Appoints Industry Veteran Jonas Jarvius, PhD as CEO

Exai Bio

Exai Bio Appoints Dave Daly as Chief Executive Officer

Exai to accelerate product development and partnering of its novel oncRNA- and generative AI-based liquid biopsy platform Dave Daly brings more than 30 years of extensive cancer diagnostics and executive leadership experience PALO ALTO, Calif. – Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced the appointment of Dave Daly as Chief Executive Officer. With more than 30 years of cancer … Continue reading Exai Bio Appoints Dave Daly as Chief Executive Officer

Broken String Biosciences

Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer

Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets CAMBRIDGE, England – Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of … Continue reading Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer